{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:24:44Z","timestamp":1790119484071,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA)","doi-asserted-by":"publisher","award":["HHSO1002019000022C"],"award-info":[{"award-number":["HHSO1002019000022C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Public Health Agency of Canada (PHAC)","award":["HHSO1002019000022C"],"award-info":[{"award-number":["HHSO1002019000022C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Marburg virus (MARV) is a negative-sense, single-stranded RNA virus that belongs to the Filoviridae family. Despite having caused numerous outbreaks of severe hemorrhagic fever with high case fatality rates, there are still no clinically approved therapeutics or vaccines to treat or prevent MARV disease. Recombinant vesicular stomatitis viruses (rVSVs) expressing heterologous viral glycoproteins have shown remarkable promise as live-attenuated vaccine vectors, with an rVSV-based Ebola virus vaccine having received regulatory approval in the United States and numerous other countries. Analogous rVSV vaccine vectors have also been developed for MARV and have shown efficacy in several preclinical studies conducted in nonhuman primates. Here, we used a guinea pig model to confirm the protective efficacy of a cloned, rVSV-based candidate vaccine, termed PHV01, expressing the MARV variant Angola glycoprotein. Our results demonstrated that a single dose (2 \u00d7 106 PFU) of vaccine administered 28 days prior to challenge with a uniformly lethal dose of guinea-pig-adapted MARV variant Angola provided complete protection from death and disease. Moreover, protection was robust, with as little as 200 PFU of vaccine conferring significant protection. Not only does this study highlight the potential predictive value of the guinea pig model in the evaluation of MARV countermeasures, but it also demonstrates consistent and reproducible protection afforded by a clonal vaccine candidate. Indeed, this study identifies PHV01 as a suitable vaccine candidate for advanced development.<\/jats:p>","DOI":"10.3390\/vaccines10071004","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T22:43:00Z","timestamp":1656024180000},"page":"1004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-9891","authenticated-orcid":false,"given":"Wenjun","family":"Zhu","sequence":"first","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Cao","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"He","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Leung","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Str\u00f6her","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5140","authenticated-orcid":false,"given":"Michael J.","family":"Fairchild","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-3400","authenticated-orcid":false,"given":"Rick","family":"Nichols","sequence":"additional","affiliation":[{"name":"Public Health Vaccines, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Crowell","sequence":"additional","affiliation":[{"name":"Public Health Vaccines, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[{"name":"Public Health Vaccines, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-2648","authenticated-orcid":false,"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"ref_1","unstructured":"Howley, P.M., Knipe, D.M., and Whelan, S. (2021). Filoviridae. Fields Virology: Emerging Viruses, Wolters Kluwer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fvl.11.79","article-title":"Clinical aspects of Marburg hemorrhagic fever","volume":"6","author":"Mehedi","year":"2011","journal-title":"Future Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/v4101878","article-title":"Forty-five years of marburg virus research","volume":"4","author":"Brauburger","year":"2012","journal-title":"Viruses"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola","volume":"80","author":"Towner","year":"2006","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection","volume":"212","author":"Geisbert","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_6","unstructured":"(2021, September 27). Guinea Declares End of Marburg Virus Disease Outbreak|WHO|Regional Office for Africa. Available online: https:\/\/www.afro.who.int\/news\/guinea-declares-end-marburg-virus-disease-outbreak."},{"key":"ref_7","unstructured":"(2022, March 28). World-Health-Organization Prioritizing Diseases for Research and Development in Emergency Contexts. Available online: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-context."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg virus vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A Vaccine against Ebola Virus","volume":"181","year":"2020","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01190-17","DOI":"10.1128\/JVI.01190-17","article-title":"Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge","volume":"92","author":"Matassov","year":"2018","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Geisbert, J.B., Agans, K.N., Satterfield, B.A., Versteeg, K.M., Fritz, E.A., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2014). Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094355"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Miller, A.D., Carville, A., Westmoreland, S.V., Geisbert, J.B., Mansfield, K.G., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2012). Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001567"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment","volume":"367","author":"Geisbert","year":"2006","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine","volume":"80","author":"Geisbert","year":"2006","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"10","author":"Marzi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"774026","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"(2021). Preparing for the next pandemic. Nat. Med., 27, 357.","DOI":"10.1038\/s41591-021-01291-z"},{"key":"ref_22","first-page":"32","article-title":"Development and characterization of a guinea pig model for Marburg virus","volume":"39","author":"Wong","year":"2018","journal-title":"Zool. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, G., Cao, W., Salawudeen, A., Zhu, W., Emeterio, K., Safronetz, D., and Banadyga, L. (2021). Vesicular stomatitis virus: From agricultural pathogen to vaccine vector. Pathogens, 10.","DOI":"10.3390\/pathogens10091092"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.3201\/eid2612.202108","article-title":"Shedding of marburg virus in naturally infected egyptian rousette bats, South Africa, 2017","volume":"26","author":"Storm","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3201\/eid2406.172165","article-title":"Marburg virus infection in egyptian rousette bats, South Africa, 2013\u20132014","volume":"24","author":"Kemp","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3201\/eid1602.091269","article-title":"Marburg virus in fruit bat, Kenya","volume":"16","author":"Kuzmin","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3201\/eid2508.190268","article-title":"Marburgvirus in Egyptian fruit bats, Zambia","volume":"25","author":"Kajihara","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Towner, J.S., Amman, B.R., Sealy, T.K., Reeder Carroll, S.A., Comer, J.A., Kemp, A., Swanepoel, R., Paddock, C.D., Balinandi, S., and Khristova, M.L. (2009). Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000536"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Amman, B.R., Carroll, S.A., Reed, Z.D., Sealy, T.K., Balinandi, S., Swanepoel, R., Kemp, A., Erickson, B.R., Comer, J.A., and Campbell, S. (2012). Seasonal Pulses of Marburg Virus Circulation in Juvenile Rousettus aegyptiacus Bats Coincide with Periods of Increased Risk of Human Infection. PLoS Pathog.","DOI":"10.1371\/journal.ppat.1002877"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-14327-8","article-title":"Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa","volume":"11","author":"Amman","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3201\/eid1508.090015","article-title":"Response to Imported Case of Marburg Hemorrhagic Fever, the Netherlands","volume":"15","author":"Timen","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/INF.0b013e3181d467bc","article-title":"Imported Case of Marburg Hemorrhagic Fever\u2014Colorado, 2008","volume":"29","author":"Leggiadro","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2020.11.042","article-title":"Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials","volume":"39","author":"Dulin","year":"2021","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","article-title":"Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?","volume":"27","author":"Meyer","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1126\/scitranslmed.abg6128","article-title":"Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects","volume":"13","author":"Meyer","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/infdis\/jiz657","article-title":"Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination","volume":"223","author":"Wagstaffe","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of ebola virus disease develop polyfunctional antibody responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:37Z","timestamp":1760139517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["vaccines10071004"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10071004","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}